This is a published Letter to the Editor of Medical Gas Research, from Dr. Paul G. Harch M.D.

Published by Wolters Kluwer – Medknow
June 2022 Vol. 13 Issue 2

New Scientific Definitions: Hyperbaric Therapy and Hyperbaric Oxygen Therapy

Dear Editor,

For nearly the entire 60-year modern era of clinical hyperbaric medicine, hyperbaric oxygen (HBO2) therapy has been defined as treatment with 100% oxygen at greater than one atmosphere absolute (ATA; clinically, ≥ 1.4 ATA), for a narrow list of diseases. These diseases have been identified by a combination of basic science, clinical studies, and expert opinion (Delphi Criteria).1 Essentially, HBO2 was defined within narrow parameters as a disease-specific therapy. It served the purpose in 1976 of establishing the foundation of a fledgling specialty in the USA by anchoring the therapy to the opinion of experts in hyperbaric medicine who then secured its reimbursement in the hospital setting. However, the clinical evidence for the list was scant for many of the 13 diagnoses at that time: no randomized controlled trials for 12 of the original 13 diagnoses and two of the last three recent additions (intracranial abscess and central retinal artery occlusion). The definition was also subject to change when one ventured outside the USA. For example, the therapy was disease-specific for 13 diseases in the USA, but disease-specific by the same and additional basic science, clinical science, and Delphi Criteria for 23 diseases in Russia, 48 in China, and 20 in Japan.2  The USA list also appeared arbitrary to non-hyperbaric medicine physicians, i.e., the bulk of the medical profession, with no apparent connection or common thread to the disparate 13 diagnoses (physicians could not see a similarity between thermal burn, air embolism, chronic refractory bone infections or the other 10 diagnoses). The common thread, however, was the treatment of disease pathophysiology that was common to the 13 diagnoses and many more.

Another critical flaw in the definition was the absence of evidence for exclusively 100% oxygen or at least 1.4 ATA of 100% oxygen.1 This historical feature is in the process of modification.  In May 2022 at the Undersea and Hyperbaric Medical Society Annual Meeting, a new definition of HBO2 was proposed that is based on the use of “near 100% oxygen (at least 95% oxygen)” with an exception for deep diving recompression treatment where the fractional inspired oxygen concentration is less than at least 95% to prevent oxygen toxicity. The new proposed definition further includes USA regulatory components, proscription of mild hyperbaric therapy/unproven applications, and exclusion of applications outside the proposed definition, none of which are pertinent to a scientific definition. Lastly, the modern-era definition has ignored both the 300-year history of hyperbaric medicine3 and the contribution of increased barometric pressure as a distinct entity.4 That history was characterized by widespread purported benefits of pressurized air, including its long-forgotten 1918 inaugural use in the USA to salvage Spanish Flu victims dying from adult respiratory distress syndrome.3 The inadequacy of the modern definition has become even more apparent with the inability to reconcile the seemingly conflicting conclusions and confusion in the multiple U.S. Department of Defense mild traumatic brain injury/persistent postconcussion syndrome studies.5

Given the aforementioned flaws, the cumulative knowledge of the bioactivity of increased barometric or hydrostatic pressure,4,5 the inescapable acknowledgment that HBO2 includes increased pressure in addition to increased pressure of oxygen,5 and the U.S. Food and Drug Administration’s identification of this dual component nature of HBO2,5 it is incumbent upon the hyperbaric medicine field to change the definition of HBO2 to embrace and account for the science underpinning it. Therefore, this is a proposal that HBO2 should be redefined as a type of hyperbaric therapy.  Hyperbaric therapy would be defined as a medical treatment that uses increased barometric pressure and increased partial pressures of breathing gases by fully enclosing a patient in a pressure vessel to treat disease pathophysiology and their diseases. Hyperbaric therapy would include any breathing gas or mixture of breathing gases with bioactivity, including argon, nitrogen, or others. HBO2 would be a subset of hyperbaric therapy where the breathing gas is near-100% oxygen (at least 95% oxygen). HBO2 would be defined as a medical treatment that uses increased barometric pressure and increased partial pressure of near 100% (at least 95%) medical grade oxygen by fully enclosing a patient in a pressure vessel to treat disease pathophysiology and their diseases. These definitions are displayed as a Venn diagram in Figure 1

Figure 1: Hyperbaric therapy and hyperbaric oxygen therapy definitions.
Note: The white circle represents the bioactivity of increased hydrostatic or barometric pressure (for tissue culture or similar experiments without a gas interface). Green circle represents hyperbaric therapy and blue circle represents hyperbaric oxygen therapy.

With these definitions, the body of knowledge on HBO2 with near 100% oxygen remains intact, while the entire history of bioactivity of lesser fractional inspired oxygen concentrations, barometric pressure, or both, and barometric pressure itself, are included. The conflicting data and confusion over shams, controls, and pseudo-shams in the U.S. Department of Defense mild traumatic brain injury studies, cerebral palsy HBO2 studies, and dozens of other studies using less than 100% oxygen and the traditional doses of 2.0–3.0 ATA become explicable and reconciled.  The new definitions would account for the entire range of science on the bioactivity of pressure, increased pressure of breathing gases, and hyperoxia and their clinical applications. They would unify the basic science field of pressure biology and clinical hyperbaric medicine and enable the subspecialty of undersea and hyperbaric medicine to encompass the entire field of medical treatment with compressed breathing gases.

Editor note: PGH is an Editorial Board member of Medical Gas Research. He was blinded from reviewing or making decisions on the manuscript. The article was subject to the journal’s standard procedures, with peer review handled independently of this Editorial Board member and their research groups.  This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Paul G. Harch*

Department of Medicine, Section of Emergency Medicine, Division of Hyperbaric Medicine, Louisiana State University School of Medicine, New Orleans, LA, USA

*Correspondence to: Paul G. Harch, MD, [email protected].

orcid: 0000-0001-7329-0078 (Paul G. Harch)

doi: 10.4103/2045-9912.356475

How to cite this article: Harch PG. New scientific definitions: hyperbaric therapy and hyperbaric oxygen therapy. Med Gas Res 2023;13(2):92-93.  Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNon-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

  1. Moon RE. Hyperbaric oxygen therapy indications. 14th ed. North Palm Beach, FL: Best Publishing Company. 2019.
  2. Jain KK. Textbook of Hyperbaric Medicine. 6th ed. Cham, Switzerland: Springer International Publishing. 2017.
  3. Trimble VH. The uncertain miracle: hyperbaric oxygenation. Garden City, NY: Doubleday & Company, Inc. 1974.
  4. Macdonald AG, Fraser PJ. The transduction of very small hydrostatic pressures. Comp Biochem Physiol A Mol Integr Physiol. 1999;122:13-36.
  5. Harch PG. Systematic review and dosage analysis: hyperbaric oxygen therapy efficacy in mild traumatic brain injury persistent postconcussion syndrome. Front Neurol. 2022;13:815056.

Date of submission: July 26, 2022

Date of decision: August 10, 2022

Date of acceptance: September 17, 2022

Date of web publication: September 28, 2022